Financial Engines Advisors Has Increased Its Abbott Laboratories Common Stock (ABT) Position; Inogen (INGN) Has 1.2 Sentiment

January 14, 2018 - By Louis Casey

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company has market cap of $2.41 billion. The companyÂ’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 93.9 P/E ratio. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

Financial Engines Advisors Llc increased Abbott Laboratories Common Stock (ABT) stake by 8.57% reported in 2017Q3 SEC filing. Financial Engines Advisors Llc acquired 13,210 shares as Abbott Laboratories Common Stock (ABT)’s stock declined 3.42%. The Financial Engines Advisors Llc holds 167,272 shares with $8.93M value, up from 154,062 last quarter. Abbott Laboratories Common Stock now has $102.42B valuation. The stock decreased 0.19% or $0.11 during the last trading session, reaching $58.84. About 6.32 million shares traded or 6.93% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 14, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

The stock increased 0.36% or $0.42 during the last trading session, reaching $115.59. About 177,929 shares traded or 16.89% up from the average. Inogen, Inc. (INGN) has risen 88.09% since January 14, 2017 and is uptrending. It has outperformed by 71.39% the S&P500.

Analysts await Inogen, Inc. (NASDAQ:INGN) to report earnings on February, 27. They expect $0.21 earnings per share, down 16.00% or $0.04 from last year’s $0.25 per share. INGN’s profit will be $4.38M for 137.61 P/E if the $0.21 EPS becomes a reality. After $0.33 actual earnings per share reported by Inogen, Inc. for the previous quarter, Wall Street now forecasts -36.36% negative EPS growth.

Brown Capital Management Llc holds 2.57% of its portfolio in Inogen, Inc. for 2.22 million shares. Tirschwell & Loewy Inc owns 165,955 shares or 2.39% of their US portfolio. Moreover, Oberweis Asset Management Inc has 1.55% invested in the company for 58,420 shares. The New York-based Atika Capital Management Llc has invested 1.34% in the stock. Cortina Asset Management Llc, a Wisconsin-based fund reported 308,756 shares.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 9 report. The firm has “Market Perform” rating by BMO Capital Markets given on Thursday, October 19. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, January 2. RBC Capital Markets maintained it with “Outperform” rating and $46 target in Thursday, January 26 report. On Thursday, October 19 the stock rating was maintained by Stifel Nicolaus with “Buy”. The rating was maintained by Cowen & Co on Tuesday, August 15 with “Buy”. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Thursday, October 19 by RBC Capital Markets. The stock has “Hold” rating by BMO Capital Markets on Monday, July 10. The firm has “Buy” rating by Cowen & Co given on Wednesday, October 18. The stock of Abbott Laboratories (NYSE:ABT) has “Neutral” rating given on Friday, October 6 by JP Morgan.

Investors sentiment decreased to 0.87 in 2017 Q3. Its down 0.01, from 0.88 in 2017Q2. It turned negative, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Roanoke Asset Mgmt Ny accumulated 51,875 shares. Bancorp Of Hawaii accumulated 69,882 shares. First Heartland Consultants holds 0.05% of its portfolio in Abbott Laboratories (NYSE:ABT) for 3,794 shares. Investment Counselors Of Maryland Limited Liability Corporation reported 0.05% in Abbott Laboratories (NYSE:ABT). Moreover, Steinberg Asset Mngmt Ltd has 1.64% invested in Abbott Laboratories (NYSE:ABT) for 87,357 shares. Excalibur reported 1.03% stake. New York-based Cobblestone Cap Limited Company Ny has invested 0.12% in Abbott Laboratories (NYSE:ABT). Klingenstein Fields Co Ltd Liability Co stated it has 35,226 shares. Foster & Motley Inc invested 0.05% of its portfolio in Abbott Laboratories (NYSE:ABT). Bancorpsouth has 0.04% invested in Abbott Laboratories (NYSE:ABT) for 6,883 shares. Somerville Kurt F stated it has 2.62% of its portfolio in Abbott Laboratories (NYSE:ABT). Bruce And holds 230,915 shares or 2.75% of its portfolio. Mcf Ltd Com reported 3,285 shares. Acropolis Invest Mngmt Limited Liability Company has invested 0.03% in Abbott Laboratories (NYSE:ABT). Mitchell Sinkler Starr Pa stated it has 23,172 shares or 1.94% of all its holdings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>